This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Naber, K. G.
Right arrow Articles by Sörgel, F.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Naber, K. G.
Right arrow Articles by Sörgel, F.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, July 1998, p. 1659-1665, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Urinary Excretion and Bactericidal Activities of a Single Oral Dose of 400 Milligrams of Fleroxacin versus a Single Oral Dose of 800 Milligrams of Pefloxacin in Healthy Volunteers

Kurt G. Naber,1,* Ursula Theuretzbacher,2 Martina Kinzig,3 Orlin Savov,1 and Fritz Sörgel3

Department of Urology, St. Elisabeth Hospital, Straubing,1 and Institute for Biomedical and Pharmaceutical Research, Nürnberg-Heroldsberg,3 Germany, and Antibiotic Center, Vienna, Austria2

Received 22 July 1996/Returned for modification 30 December 1996/Accepted 27 April 1998

Twelve healthy volunteers participated in this randomized crossover study to compare the concentrations and recovery levels of fleroxacin and pefloxacin in urine and to assess their bactericidal activities against 12 strains of urinary pathogens with different susceptibilities over a wide range of MICs. The volunteers received a single oral dose of 400 mg of fleroxacin or 800 mg of pefloxacin. The mean cumulative renal excretion of unchanged fleroxacin, N-demethyl-fleroxacin, and N-oxide-fleroxacin accounted for 67, 7, and 6% of the total dose, respectively. The total urinary recovery of pefloxacin and the active metabolite norfloxacin was 34%. In the time-kill and the urinary bactericidal titer (UBT) studies, only the subjects' urine not supplemented with broth was used. With most tested organisms and both quinolones it took more than 8 h to achieve a reduction in CFU of 99.9% (3 log units). Overall, there was a good correlation between UBTs and MICs for the strains. Against Escherichia coli ATCC 25922 the median UBTs were similar for both antibiotics and at least 1:8 for 96 h; against the E. coli strain for which the MIC was 0.5 µg/ml the UBT was at least 1:4 for 48 h. The UBTs of both drugs against Klebsiella pneumoniae were at least 1:16 for 72 h. The UBTs for Staphylococcus aureus (the MIC for which was 16 µg/ml) of both antibiotics were low, and in some of the samples, no bactericidal titers were observed. UBTs for Proteus mirabilis of pefloxacin are significantly higher than those of fleroxacin. For Pseudomonas aeruginosa the median UBTs were present for the 24-to-48-h interval. The same is true for Enterococcus faecalis. Against Staphylococcus saprophyticus, UBTs were present for at least 48 h with both quinolones. Overall, a single oral dose of 400 mg of fleroxacin exhibits UBTs comparable to those of 800 mg of pefloxacin. Therefore, it may be expected that half of the dose of fleroxacin gives comparable results in the treatment of urinary tract infections; this should be substantiated in comparative clinical trials.

* Corresponding author. Mailing address: Department of Urology, St. Elisabeth Hospital, St. Elisabethstr. 23, D-94315 Straubing, Germany. Phone: (9421) 710 1700. Fax: (9421) 710 270.

Antimicrobial Agents and Chemotherapy, July 1998, p. 1659-1665, Vol. 42, No. 7
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Wagenlehner, F. M. E., Wagenlehner, C., Redman, R., Weidner, W., Naber, K. G. (2009). Urinary Bactericidal Activity of Doripenem versus That of Levofloxacin in Patients with Complicated Urinary Tract Infections or Pyelonephritis. Antimicrob. Agents Chemother. 53: 1567-1573 [Abstract] [Full Text]  
  • Wagenlehner, F. M. E., Kinzig-Schippers, M., Tischmeyer, U., Wagenlehner, C., Sorgel, F., Naber, K. G. (2006). Urinary Bactericidal Activity of Extended-Release Ciprofloxacin (1,000 Milligrams) versus Levofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. Antimicrob. Agents Chemother. 50: 3947-3949 [Abstract] [Full Text]  
  • Wagenlehner, F. M. E., Wydra, S., Onda, H., Kinzig-Schippers, M., Sorgel, F., Naber, K. G. (2003). Concentrations in Plasma, Urinary Excretion, and Bactericidal Activity of Linezolid (600 Milligrams) versus Those of Ciprofloxacin (500 Milligrams) in Healthy Volunteers Receiving a Single Oral Dose. Antimicrob. Agents Chemother. 47: 3789-3794 [Abstract] [Full Text]  
  • Naber, C. K., Hammer, M., Kinzig-Schippers, M., Sauber, C., Sorgel, F., Bygate, E. A., Fairless, A. J., Machka, K., Naber, K. G. (2001). Urinary Excretion and Bactericidal Activities of Gemifloxacin and Ofloxacin after a Single Oral Dose in Healthy Volunteers. Antimicrob. Agents Chemother. 45: 3524-3530 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»